Two selected reports cover intravenous ipamorelin in bowel-surgery patients and pharmacology in healthy men. Other routes, combinations and proposed uses are outside these findings.12
Bottom line from this bounded source set
The postoperative-ileus trial found no statistically significant improvement in its key or secondary efficacy analyses. The healthy-volunteer study measured growth hormone responses, which do not establish clinical benefit.12
Reviewed study record
Postoperative ileus: a placebo-controlled phase 2 trial
Design
A multicenter blinded randomized placebo-controlled study assessed recovery after bowel resection.1
Population
The trial enrolled 117 adults; 114 were included in its safety and modified intent-to-treat populations.1
Outcomes reported
Time to a tolerated solid meal was not significantly different between groups. Treatment-emergent adverse events occurred in 87.5% with ipamorelin and 94.8% with placebo.1
Limitations
The study was small and included varied underlying conditions. A nonsignificant result does not prove equivalence, and these postoperative findings do not establish safety for other uses or routes.1
Reviewed study record
Healthy-volunteer pharmacokinetics and hormone response
Design
An escalating-exposure study modeled drug concentrations and growth hormone responses.2
Population
The report describes eight healthy men at each of five exposure levels.2
Outcomes reported
The study observed an episode of growth hormone release and substantial between-person variability in pharmacodynamic responses.2
Limitations
The endpoints were pharmacology and hormone measurements, not clinical benefits. The abstract does not provide enough adverse-event detail for a safety conclusion.2
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1007/s00384-014-2030-8. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1023/a:1018955126402. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗